192 related articles for article (PubMed ID: 36400307)
21. A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer.
Zhu SL; Qi M; Chen MT; Lin JP; Huang HF; Deng LJ; Zhou XW
Phytomedicine; 2024 Jun; 128():155377. PubMed ID: 38503154
[TBL] [Abstract][Full Text] [Related]
22. The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
Awasthi N; Yen PL; Schwarz MA; Schwarz RE
J Cell Biochem; 2012 Mar; 113(3):784-91. PubMed ID: 22020918
[TBL] [Abstract][Full Text] [Related]
23. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Gifford JB; Huang W; Zeleniak AE; Hindoyan A; Wu H; Donahue TR; Hill R
Mol Cancer Ther; 2016 May; 15(5):1043-52. PubMed ID: 26939701
[TBL] [Abstract][Full Text] [Related]
24. Berberine enhances gemcitabine‑induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway.
Gao X; Liu J; Fan D; Li X; Fang Z; Yan K; Fan Y
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34935059
[TBL] [Abstract][Full Text] [Related]
25. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
26. CCL26 is upregulated by nab-paclitaxel in pancreatic cancer-associated fibroblasts and promotes PDAC invasiveness through activation of the PI3K/AKT/mTOR pathway.
Chen X; An Y; Zhang Y; Xu D; Chen T; Yang Y; Chen W; Wu D; Zhang X
Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):612-619. PubMed ID: 33764366
[TBL] [Abstract][Full Text] [Related]
27. LncRNA AB209630 inhibits gemcitabine resistance cell proliferation by regulating PI3K/AKT signaling in pancreatic ductal adenocarcinoma.
Wang L; Wang F; Na L; Yu J; Huang L; Meng ZQ; Chen Z; Chen H; Ming LL; Hua YQ
Cancer Biomark; 2018; 22(1):169-174. PubMed ID: 29526843
[TBL] [Abstract][Full Text] [Related]
28. Modulated Electro-Hyperthermia Supports the Effect of Gemcitabine Both in Sensitive and Resistant Pancreas Adenocarcinoma Cell Lines.
Forika G; Kiss E; Petovari G; Danko T; Gellert AB; Krenacs T
Pathol Oncol Res; 2021; 27():1610048. PubMed ID: 34955688
[TBL] [Abstract][Full Text] [Related]
29. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
30. Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway.
Zhou Y; Zhou Y; Yang M; Wang K; Liu Y; Zhang M; Yang Y; Jin C; Wang R; Hu R
Redox Biol; 2019 Apr; 22():101131. PubMed ID: 30735911
[TBL] [Abstract][Full Text] [Related]
31. Nuclear MAST4 Suppresses FOXO3 through Interaction with AKT3 and Induces Chemoresistance in Pancreatic Ductal Carcinoma.
Fujiwara-Tani R; Sasaki T; Bhawal UK; Mori S; Ogata R; Sasaki R; Ikemoto A; Kishi S; Fujii K; Ohmori H; Sho M; Kuniyasu H
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612866
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
Li YJ; Wang Y; Wang YY
J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine and Selected mTOR Inhibitors in Uterine Sarcomas and Carcinosarcoma Cells- an Isobolographic Analysis.
Bobiński M; Okła K; Łuszczki J; Bednarek W; Wawruszak A; Moreno-Bueno G; Garcia-Sanz P; Dmoszyńska-Graniczka M; Tarkowski R; Kotarski J
Int J Med Sci; 2020; 17(18):2987-2997. PubMed ID: 33173419
[No Abstract] [Full Text] [Related]
34. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.
Totiger TM; Srinivasan S; Jala VR; Lamichhane P; Dosch AR; Gaidarski AA; Joshi C; Rangappa S; Castellanos J; Vemula PK; Chen X; Kwon D; Kashikar N; VanSaun M; Merchant NB; Nagathihalli NS
Mol Cancer Ther; 2019 Feb; 18(2):301-311. PubMed ID: 30404927
[TBL] [Abstract][Full Text] [Related]
35. AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor.
Ingle K; LaComb JF; Graves LM; Baines AT; Bialkowska AB
PLoS One; 2023; 18(11):e0294065. PubMed ID: 37943821
[TBL] [Abstract][Full Text] [Related]
36. Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Ozpolat B; Akar U; Zorrilla-Calancha I; Vivas-Mejia P; Acevedo-Alvarez M; Lopez-Berestein G
Apoptosis; 2008 Jul; 13(7):915-28. PubMed ID: 18491231
[TBL] [Abstract][Full Text] [Related]
37. VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-κB activity in B cell precursor-acute lymphoblastic leukemia.
Toosi B; Zaker F; Alikarami F; Kazemi A; Teremmahi Ardestanii M
Biomed Pharmacother; 2018 Jun; 102():428-437. PubMed ID: 29574283
[TBL] [Abstract][Full Text] [Related]
38. HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway.
Zhao F; Yang G; Qiu J; Liu Y; Tao J; Chen G; Su D; You L; Zheng L; Zhang T; Zhao Y
Mol Carcinog; 2022 Sep; 61(9):839-850. PubMed ID: 35785493
[TBL] [Abstract][Full Text] [Related]
39. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
40. Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone.
Esmaeili S; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Salari S; Gharehbaghian A; Hamidpour M; Bashash D
Int J Biochem Cell Biol; 2020 May; 122():105739. PubMed ID: 32169580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]